Together, these studies indicate that the primary mechanism of action for imatinib efficacy in T1D is not through inhibition of c-Kit but probably through inhibition of other tyrosine kinase receptor targets such as c-Abl or PDGFR. This evidence concerns the gene KIT and type 1 diabetes mellitus.